1. Home
  2. ENTX vs GRX Comparison

ENTX vs GRX Comparison

Compare ENTX & GRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Entera Bio Ltd.

ENTX

Entera Bio Ltd.

HOLD

Current Price

$2.16

Market Cap

142.0M

Sector

Health Care

ML Signal

HOLD

Logo The Gabelli Healthcare & Wellness Trust of Beneficial Interest

GRX

The Gabelli Healthcare & Wellness Trust of Beneficial Interest

HOLD

Current Price

$9.60

Market Cap

147.2M

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
ENTX
GRX
Founded
2010
2007
Country
Israel
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Finance/Investors Services
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
142.0M
147.2M
IPO Year
2018
N/A

Fundamental Metrics

Financial Performance
Metric
ENTX
GRX
Price
$2.16
$9.60
Analyst Decision
Strong Buy
Analyst Count
1
0
Target Price
$10.00
N/A
AVG Volume (30 Days)
82.8K
39.7K
Earning Date
11-14-2025
01-01-0001
Dividend Yield
N/A
5.98%
EPS Growth
N/A
N/A
EPS
N/A
0.26
Revenue
$124,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
$38.50
Revenue Growth
25.25
N/A
52 Week Low
$1.50
$7.73
52 Week High
$3.22
$10.40

Technical Indicators

Market Signals
Indicator
ENTX
GRX
Relative Strength Index (RSI) 36.71 57.61
Support Level $2.05 $9.47
Resistance Level $2.53 $9.71
Average True Range (ATR) 0.22 0.09
MACD -0.07 0.01
Stochastic Oscillator 13.42 62.71

Price Performance

Historical Comparison
ENTX
GRX

About ENTX Entera Bio Ltd.

Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to significantly shift a treatment paradigm. Its product candidates are; EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are first-in-class mini tablet formulations of synthetic human PTH (1-34) (teriparatide), designed to have differing pharmacokinetic, or PK, profiles.

About GRX The Gabelli Healthcare & Wellness Trust of Beneficial Interest

Gabelli Healthcare & WellnessRx Trust operates as a diversified closed-end management investment company. The investment objective of the fund is the long-term growth of capital. The fund invests at least its assets in equity securities and income-producing securities of domestic and foreign companies in the healthcare and wellness industries. It invests in various sectors, of which Health Care Providers & Services, Food, Health Care Equipment and Supplies, and Pharmaceuticals account for the majority of the weightage.

Share on Social Networks: